RESEARCH ARTICLE

Ability of device to collect bacteria from cough aerosols generated by adults with cystic fibrosis [version 1; peer review: 2 approved]

David N. Ku^{1,2}, Sarah K. Ku², Beth Helfman^{3,4}, Nael A. McCarty^{3,4}, Bernard J. Wolff⁵, Jonas M. Winchell⁵, Larry J. Anderson⁶

¹Georgia Institute of Technology, Atlanta, GA, 30332, USA

²MD Innovate, Inc, Decatur, GA, 30030, USA

³Emory Children's Center for Cystic Fibrosis Research, Emory University, Atlanta, GA, 30322, USA

⁴Department of Pediatrics, Emory University, Atlanta, 30322, USA

⁵Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, 30333, USA

⁶Division of Infectious Diseases, Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, GA, 30322, USA

V1 First published: 05 Aug 2016, 5:1920
<https://doi.org/10.12688/f1000research.9251.1>

Latest published: 05 Aug 2016, 5:1920
<https://doi.org/10.12688/f1000research.9251.1>

Abstract

Background: Identifying lung pathogens and acute spikes in lung counts remain a challenge in the treatment of patients with cystic fibrosis (CF). Bacteria from the deep lung may be sampled from aerosols produced during coughing.

Methods: A new device was used to collect and measure bacteria levels from cough aerosols of patients with CF. Sputum and oral specimens were also collected and measured for comparison. *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, and *Streptococcus mitis* were detected in specimens using Real-Time Polymerase Chain Reaction (RT-PCR) molecular assays.

Results: Twenty adult patients with CF and 10 healthy controls participated. CF related bacteria (CFRB) were detected in 13/20 (65%) cough specimens versus 15/15 (100%) sputum specimens. Commensal *S. mitis* was present in 0/17 (0%, $p=0.0002$) cough specimens and 13/14 (93%) sputum samples. In normal controls, no bacteria were collected in cough specimens but 4/10 (40%) oral specimens were positive for CFRB.

Conclusions: Non-invasive cough aerosol collection may detect lower respiratory pathogens in CF patients, with similar specificity and sensitivity to rates detected by BAL, without contamination by oral CFRB or commensal bacteria.

Keywords

Cystic fibrosis, aerosols, specimen collection, respiratory infections, etiology

Open Peer Review

Approval Status

	1	2
version 1
05 Aug 2016	view	view
1. Mats Kalin , Karolinska Institutet, Stockholm, Sweden		
2. David E Griffith , The University of Texas Health Center at Tyler, Tyler, USA		
Any reports and responses or comments on the article can be found at the end of the article.		

Corresponding author: David N. Ku (david.ku@me.gatech.edu)

Competing interests: Dr. David N. Ku, Sarah K. Ku, and Dr. Larry J. Anderson are co-inventors on the PneumoniaCheck™ patent licensed to MD Innovate, Inc. from US Centers for Disease Control and Prevention and Georgia Tech Research Corporation.

Grant information: Supported by internal grants from US Centers for Disease Control and Prevention and Emory University Hospital. *The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

Copyright: © 2016 Ku DN *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Ku DN, Ku SK, Helfman B *et al.* **Ability of device to collect bacteria from cough aerosols generated by adults with cystic fibrosis [version 1; peer review: 2 approved]** F1000Research 2016, **5**:1920 <https://doi.org/10.12688/f1000research.9251.1>

First published: 05 Aug 2016, **5**:1920 <https://doi.org/10.12688/f1000research.9251.1>

Introduction

The etiology of lower respiratory tract infections in the lungs is difficult to determine, in part because a good quality specimen from the site of the infection is not readily available¹⁻⁴. Access to such a specimen would be an important advance in the monitoring and treatment of cystic fibrosis (CF), as well as other lower respiratory tract infections, such as pneumonia, tuberculosis, asthma, lung cancer, etc. Presently, oropharyngeal (OP), sputum, and bronchoalveolar lavage (BAL) specimens are typically used to monitor CF patients. OP specimens may be appropriate for detecting viruses, but are not ideal for most bacterial pathogens. Sputum is commonly collected to monitor CF but often contains contaminants and cystic fibrosis related bacteria (CFRB) from the upper respiratory tract. The difficulty some patients have in producing an acceptable sputum specimen further decreases the value of these samples, often causing the physician to treat the patient empirically¹⁻⁴. BAL provides a specimen from the lungs but is an invasive procedure that cannot be routinely used. BAL specimens may also collect contaminants from the upper respiratory tract⁵⁻⁷.

An alternative source for a lung specimen is from aerosols generated during coughs⁸⁻¹². Studies show that one cough can generate as many as 66,000 expelled particles^{10,13}. Patients that have lower respiratory tract infections can infect others through respiratory dispersion of pathogens in aerosols generated by coughing or sneezing. Coughing produces a higher concentration of pathogens from the lower lungs than normal exhalation or sneezing⁸⁻¹³. A new cough specimen collection device (PneumoniaCheck™, Figure 1) collects aerosols from the lungs onto a micropore filter while minimizing

Figure 1. PneumoniaCheck™ specimen storage and transport container.

contamination from the upper respiratory tract. Microbiology or molecular assays can then be used to detect pathogens collected on the device's filter.

The device uses a reservoir to separate oral contents from deep lung aerosols using fluid mechanics for separation (Figure 2). The initial volume of air that comes from exhalation or coughing is contaminated air from the upper respiratory tract, also known as anatomic dead space. When a patient coughs into the device, this air from the upper airways first flows into the reservoir (Figure 2a). The exhaled air flows to the reservoir first as it has the least resistance compared

Figure 2. PneumoniaCheck™ fluid mechanics airway separation. (a) Contaminated upper airway particles from the mouth initially fill up air reservoir. **(b)** Then, uncontaminated lower airway particles from the lungs are captured onto filter.

to the filter at the end of the device. This reservoir has a volume of 250 ml, approximately 100 ml greater than the volume of anatomic dead space in the average adult¹⁵, which ensures that all of the upper airway aerosols are completely separated out. The expanded reservoir is inelastic, creating a back-pressure, so subsequent exhaled breath is forced through the microbial filter (Figure 2b). Therefore, only lung aerosol contents are collected onto the filter and are free from upper airway contamination.

A previous study demonstrated that the device's filter is >99% effective in collecting airborne bacteria (approximately 3.1 µm in diameter) and viruses (approximately 2.8 µm in diameter)¹⁶. Sampling from normal individual controls showed zero collection of oral contents on the filter, even with up to 15 ml of liquid in the mouth (simulating sputum). The PneumoniaCheck™ device has been shown to significantly separate the lower airway gas from the upper airway gas based on oxygen and alcohol levels ($p < 0.0001$)¹⁶.

CF is a genetic disease that affects the lungs of approximately 28,000 children and adults in the United States each year¹⁷. People with CF often have chronic lung infections and require regular monitoring to ensure that bacterial colonization does not develop into infection^{26,27}. We used specimens from sputum and coughs to compare their abilities to capture, identify, and quantify relative levels of lung bacteria in adult CF patients. The goal of this study is to determine if the cough device can capture lung pathogens from adult patients with chronic lung infection while simultaneously excluding oral bacteria.

Materials and methods

Subjects

Patients with CF (n=20) aged >18 years old were recruited from the Emory Cystic Fibrosis Center Adult Clinic in Atlanta, Georgia. The Emory Institutional Review Board (H08353) approved the study and participants provided their written, informed consent. The sample size was sufficiently powered to demonstrate statistical significance for lower lung sampling without oral contamination. Tests of paired proportions were conducted using an exact form of the McNemar test to compare the presence of CFRB between two samples (i.e. cough and sputum). The Wilcoxon signed rank test was used to compare cycle threshold (C_T) values between the different methods of sampling. The C_T value of 60 was used as the upper limit of detection for all PCR assays to determine relative quantity of bacteria in each specimen.

Clinical measurements

Throat swabs and cough device specimens were collected from 10 healthy, non-smoking subjects for normal controls. Separately, a sputum specimen and cough device specimen were each collected from 20 adult patients with CF. Cough device specimen collection preceded sputum specimen collection in order to help induce sputum. Specimen collections were supervised and emergency equipment was readily available. *Streptococcus mitis* is a commensal bacterium that is found in the mouth but not in the lungs¹⁴. *Streptococcus pneumoniae* and *Staphylococcus aureus* are also commonly found in the oral cavity³. *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Klebsiella pneumoniae* are cystic fibrosis related bacteria (CFRB)^{18–20}. Oral and cough specimens

were analyzed for these bacteria to determine levels of oral contamination.

Determining sufficient aerosol collection

Fennelly's Cough Aerosol Sampling System (CASS)^{29,30} and Knibbs' Distance Rig¹³ have demonstrated that cough particles can carry substantial concentrations of bacteria from lower respiratory infections. A previous article on the cough collection device describes the ability of the device to selectively sample from the lower lungs while excluding oral contaminants¹⁶. The cough device used in this study provides a less cumbersome option to Fennelly's and Knibbs' methods for lung specimen collection. Each patient coughed 10 times into the device to ensure sufficient aerosol collection.

Microbiology

Microbiology culturing has several limitations that decrease the efficiency and effectiveness of rapid diagnosis²⁴. Throat, sputum, and cough specimens were all analyzed using molecular PCR methods. All specimens were processed in a BSL 2 safety cabinet. The cough device filter was removed, placed into a 2 ml sterile freezer vial, and stored at -80°C. Respiratory secretions captured on the filter were removed by hydrating the filter with 1 mL of lysis buffer (MagNA Pure LC lysis buffer; Roche Applied Science, Indianapolis, IN), vortexing, incubating for 5 min at room temperature, and collected using a pipette. Fluid remaining in the filter was collected by placing the filter in a sterile Costar SpinX microfuge tube with a 0.45 micron filter (Corning Inc., Corning, NY), centrifuging for 1 min at 10,000 rpm, and retrieved using a pipette. The residual fluid was then combined with original collected fluid and then 400 µL was extracted on the MagNA Pure Compact Instrument (Roche Applied Science) per the manufacturer's instructions. The extracted nucleic acid was eluted into 100 µL of elution buffer and stored at -80°C for qPCR testing.

The sputum specimen was mixed with 1 mL of phosphate buffered saline (PBS), homogenized with pipetting and vortexing, mixed with a 12.5 mM equal volume of freshly prepared dithiothreitol (DTT, No Weigh™ format, Fisher Scientific), and incubated at room temperature for 30 min with periodic vortexing. The resultant solution was divided into 400 µL aliquots and stored at -80°C. A 400 µL aliquot of the processed sample was then extracted on the MagNA Pure Compact Instrument and stored as described above.

The extracted nucleic acid was tested for *P. aeruginosa*, *S. aureus*, *K. pneumoniae*, and *S. mitis* targets by individual real-time PCR assays. The primer and probe sequences for these assays have been previously described²⁵. The *S. mitis* primers are: Forward TTTT-GTCATCTAGCCTTGC; Reverse GCAGTCATATCATCACCTTC and Probe ACTTGGGCAATCCCGACAGATTCTAAC, with a 5' FAM reporter and a 3' BHQ quencher. The PCR reactions were done with 5 µl of extracted nucleic acid from the specimens plus 12.5 µl of PerfeCTa Multiplex qPCR SuperMix (catalog no. 95063-200; Quanta BioSciences), 0.5 µM final concentrations of each primer, 0.1 µM final concentration of the probe, and nuclease-free water (catalog no. P1193; Promega) to a final reaction volume of 25 µL. Real-time PCR reactions were performed using an ABI 7500 standard machine (Life Technologies, Carlsbad, CA)

with enzyme activation at 95°C for 5 min, followed by 45 cycles of 95°C for 15 seconds and 60°C for 1 min. All specimens from CF patients were run in duplicate for each target. The C_T values for individual PCR assays were used as an indication of the relative quantity of bacteria in the specimen.

Results

All subjects completed specimen collection safely. Ten healthy subjects were used for controls. Sputum and cough specimens were successfully collected from 20 adult patients with CF, with the exception of five patients who could not produce a sputum specimen.

Normal controls demonstrated a high incidence of false positives from oral sampling, shown in Table 1. Bacteria were isolated from throat swabs in 4/10 (40%) normal, healthy control subjects. *S. pneumoniae* was positive in 2/10 (20%) oral specimens and *S. aureus* was positive in 3/10 (30%) oral specimens, with one subject positive for both bacteria. In contrast, 0/10 (0%, $p=0.0313$) cough specimens were positive for bacteria in normal controls. The calculated true negative rate or specificity for sputum specimens was 60% and 100% for cough specimens.

Specificity in the CF patients was similar. For the CF patients, *S. mitis* was isolated from 13/14 (93%) sputum specimens but in none of the cough specimens (0%, $p=0.0002$). The cough specimens collected no *S. mitis*. CFRB was collected in both specimen types. *P. aeruginosa* was isolated from 13/15 (87%) sputum specimens and 9/20 (45%) cough specimens ($p=0.0213$). *S. aureus* was isolated from 9/15 (60%) sputum specimens and 3/20 (15%) cough specimens. *K. pneumoniae* was isolated from 2/15 (13%) sputum specimens and 3/20 (15%) cough specimens.

In aggregate, sputum specimens were positive for CFRB in 15/15 (100%) samples. Cough specimens were positive for CFRB in 13/20 (65%) samples. The sputum specimens had a 93% rate of oral

commensals. Sputum specimens were positive for three or more pathogens in 2/15 (13%) samples, and positive for two or more pathogens in 7/15 (47%) samples. In contrast, cough specimens had no commensals and were positive in 65% of the CF patients. The cough specimens were positive for two or more pathogens in 2/20 (10%, $p<0.05$) specimens and no cough specimens were positive for three or more pathogens. The results of these real-time PCR identifications are listed in Table 2.

C_T values are inversely proportional to the quantity of bacteria in a sample, i.e. small values indicate higher quantities of colony forming units (CFU). For the CFRB samples, *P. aeruginosa* C_T values ranged from 18–33 in sputum specimens and 33–42 in cough specimens. *S. aureus* C_T values ranged from 24–38 in sputum specimens and 36–40 in cough specimens. For both *P. aeruginosa* and *S. aureus* the cough and sputum specimens significantly differed in C_T values ($p=0.0017$ and 0.0092 , respectively). *K. pneumoniae* C_T values ranged from 37–38 in sputum specimens and 39–43 in cough specimens. Thus, the C_T values for cough specimens were consistently higher than those of sputum. Note that the cough filter samples from normal controls exhibited no pathogens up to C_T values of 60.

Discussion

It is widely recognized that a simple, safe, non-invasive, low maintenance, inexpensive, widely accessible sampler is needed for the collection of lower respiratory pathogens^{34–37}.

Collection of lower lung contents by coughing is much easier than BAL specimen collection. The method is convenient for patients who are already inclined to cough and they reported that the use of the device helped clear their lungs. Cough specimens may provide a non-invasive yet specific sample for in-home surveillance to watch for spikes in lung pathogens in patients with CF. Use of the device to collect cough aerosols has the potential to provide a clean alternative to oral samples for detecting lower lung pathogens.

Table 1. Detection of bacteria in throat and cough specimens from normal, healthy controls.

	Throat	Cough
1	<i>S. aureus</i>	Negative
2	Negative	Negative
3	Negative	Negative
4	<i>S. aureus</i>	Negative
5	<i>S. aureus</i> , <i>S. pneumoniae</i>	Negative
6	Negative	Negative
7	Negative	Negative
8	<i>S. pneumoniae</i>	Negative
9	Negative	Negative
10	Negative	Negative

Table 2. Detection of bacteria in sputum and cough specimens from adult CF patients.

	Sputum			Cough		
	n=15*	%	C_T range	n=20	%	C_T range
<i>P. aeruginosa</i>	13/15	87%	18–33	9/20	45%	33–42
<i>S. aureus</i>	9/15	60%	24–38	3/20	15%	36–40
<i>K. pneumoniae</i>	2/15	13%	37–38	3/20	15%	39–43
CFRB total	15/15	100%	18–38	13/20	65%	33–43
2+ pathogens	7/15	47%	18–38	2/20	10%	36–43
3+ pathogens	2/15	13%	18–38	0/20	0%	N/A
<i>S. mitis</i>	13/14†	93%	24–41	0/17‡	0%	N/A

* Five patients were unable to produce viable sputum specimens

† Six sputum specimens were not tested for *S. mitis*

‡ Three cough specimens were not tested for *S. mitis*

As is well known, commonly used samples of sputum or OP swabs show strong contamination in the upper airway^{3,4}. Nearly all of the sputum specimens were positive for the oral commensal *S. mitis*. In contrast, none of the cough specimens were positive for *S. mitis*. This difference in the commensal *S. mitis* between sputum and cough specimens reiterates the unreliability and low specificity of sputum^{3,4}. Further, not all patients can produce an adequate sputum sample. Examining the 12 subjects with paired sputum and *S. mitis* results, 8/12 (67%) sputum and cough specimens had concordant positives, although six of these eight were positive for additional bacteria in sputum. These six sputum specimens with multiple bacteria likely indicate false positives from oral contamination rather than co-infection.

The number of concordant sputum and cough specimens (2/12, 17%) was small. Conversely, the pathogen detected in the cough specimen was different from that observed in the sputum specimen. 2/12 (17%) sputum specimens did not identify bacteria that were identified in cough specimens, possibly reflecting masked readings associated with commensal distraction. The differences demonstrate that the cough device is not just collecting sputum.

P. aeruginosa is the most common bacterium found in lungs of adult CF patients¹⁹, and was also the most prevalent bacterium collected in our cohort. 13/20 (65%) cough specimens were positive for CFRB. This incidence and distribution of pathogens in CF is similar to the 59% positive for CFRB in BAL sampling^{22,23}. Prior series of BAL specimens in similar populations have yielded positive CFRB of 59–85%, similar to the 65% positivity from the cough device illustrating comparable sensitivity^{22,23}.

Collection of exhaled aerosols has been studied by several previous groups. An alternate device for aerosol collection is the RTube™; however, it varies greatly in design and function²⁸. The RTube™ system is designed to collect from all exhaled breath that condenses²⁸ while PneumoniaCheck™ is designed to collect particulate sized lung aerosols and separate out the mouth contents¹⁶. The majority of exhaled gas passes out of the end of the RTube™ as only water condensate is intended to be collected. Exhaled breath condensate can be a useful specimen for identifying pH levels, but is generally not viewed as a reliable specimen for identifying lower respiratory infections^{34–37}.

Wainwright *et al.*, reported detecting *P. aeruginosa* in cough aerosols by culture¹². They reported 25/28 (89%) positive in a mixed population of children and adults with CF using a cough aerosol sampling system (CASS) for 5 minutes with each subject¹². Similarly, Knibbs *et al.* reported that 14/18 (78%) patients aerosolized *P. aeruginosa* that remained viable and presumably transmissible up to 45 minutes after coughs sampled on an Anderson impactor¹³. Knibbs *et al.* used conventional microbiology cultures to quantify colony forming units. Both of these studies used a specially constructed aerosol sampler that is expensive, cumbersome, and difficult to use in a clinical setting. For these studies, patients cough into a standard mouthpiece and aerosols are sucked into impactors

using vacuum air pumps. The CASS system was not designed for routine use in clinical settings and the mouthpiece was not designed to exclude oral contents. These designs differ from PneumoniaCheck™, which has a mouthpiece designed to specifically exclude oral contaminants¹⁶. The high incidence of *P. aeruginosa*, using the snorkel type mouthpiece and tubing, may reflect some collection of oral contents using CASS.

RT-PCR may be used to quantify the amount of pathogens in a sample. As more material is collected on the filter, the C_T counts will drop similar to the inverse of CFUs³². It should be noted that an aerosolized lung specimen should have higher C_T values compared to the liquid specimens of sputum due to a lack of contamination and the small physical volume of aerosols. C_T values in the sputum specimens ranged from 19–38, whereas the range in cough specimens was 33–43 ($p < 0.001$, Table 3). Nonetheless, C_T values in all positive cough specimens are significantly lower than the baseline of >60 for normal controls. While the C_T values are higher for the cough specimens, the background noise level of the virgin filter is >60 , allowing limits of detection by PCR that may be more sensitive to lung CFRB.

One can utilize the C_T values to compare relative amounts of pathogens being coughed by an individual patient compared with a population^{32,33}. Jones-López *et al.* found that both CF and TB patients can produce aerosols with viable pathogens, but the amount of pathogens produced by individuals varies greatly³¹. Patients with high amounts of *M. tuberculosis* in cough aerosols were more likely to have transmitted to others³⁰. Those that produce large amounts of pathogens in coughs may be more efficient transmitters, e.g. “superspreaders”^{13,30}. The quantity of pathogens in a cough may be a critical metric in transmission of infectious disease, controlling epidemics, and monitoring colonization. In the Jones-López *et al.* study, the amount of aerosolized *M. tuberculosis* fell dramatically after three weeks of treatment. Therefore, a cough specimen could also be used to monitor levels of resistant bacteria, if present.

Published guidelines for CF patients suggest acquiring quarterly respiratory specimens to monitor lung infections^{26,27}. Cough specimens may be a more specific and sensitive method for monitoring colonization and determining infectivity. Additional studies could explore this application further by comparing C_T values with symptoms. If a CF patient is monitored on a regular basis using cough specimens, a sudden decrease in C_T value may indicate a change in pathogen burden^{32,33}. The C_T value of pathogen burden in cough aerosols may be useful as a measurement to determine if the lung burden is growing.

This study has several limitations. Our study included only adult patients; thus, we cannot comment on the aerosol production during coughing by pediatric patients. This study reports on 20 patients. Most studies in the literature have a similar number of subjects, since lower respiratory identification has always been an enormous challenge^{12,13}. Future studies may evaluate the benefits of requiring

Table 3. C_T values of sputum and cough specimens grouped by pathogen.

Subject #	<i>P. aeruginosa</i>		<i>S. aureus</i>		<i>K. pneumoniae</i>		<i>S. mitis</i>	
	Sputum	Cough	Sputum	Cough	Sputum	Cough	Sputum	Cough
1	22	33	-	-	-	-	41	-
2	N/A	42	N/A	-	N/A	-	N/A	-
3	32	-	-	-	-	-	32	-
4	21	41	36	-	-	-	24	-
5	N/A	-	N/A	-	N/A	-	N/A	-
6	18	-	-	-	-	41	32	-
7	N/A	-	N/A	-	N/A	-	N/A	-
8	N/A	35	N/A	-	N/A	-	N/A	-
9	N/A	-	N/A	36	N/A	43	31	-
10	19	-	38	40	37	-	N/A	N/A
11	19	42	27	-	38	-	N/A	N/A
12	20	-	-	-	-	-	30	-
13	33	39	30	-	-	-	33	-
14	33	40	24	-	-	-	33	-
15	-	-	37	-	-	-	32	-
16	25	-	-	-	-	-	31	-
17	-	-	33	-	-	39	27	-
18	25	-	-	-	-	-	29	-
19	25	39	29	39	-	-	29	-
20	22	42	34	-	-	-	-	N/A

more coughs or coughing for a specified amount of time, such as 5 minutes, to establish C_T thresholds for this new method of specimen collection. The RT-PCR molecular assays used in this study are not available at all hospitals, although a few commercial laboratories can provide clinical respiratory identification services.

Conclusion

In summary, we have shown that a new device can collect lung pathogens from adult patients with CF from cough aerosols with identification using molecular assays. The device excludes oral contaminants showing higher specificity than sputum samples. Identifying causative pathogens in the lower respiratory tract is likely to play a significant role in patient management²⁴. The data in this study suggest an alternative to sputum collection for the identification of lower respiratory pathogens.

Consent

Written informed consent was obtained by all participants through Institutional Review Board Protocol #000-2492 approved by Georgia Institute of Technology, Emory University, and US Centers for Disease Control and Prevention.

Data availability

All raw data are provided in the tables above.

Author contributions

David N. Ku, Nael A. McCarty, Bernard J. Wolff, Jonas M. Winchell, and Larry J. Anderson served as scientific advisors. Beth Helfman collected data and provided and cared for study patients. Sarah K. Ku wrote and edited much of the manuscript. All authors agreed to the final content of the article.

Competing interests

Dr. David N. Ku, Sarah K. Ku, and Dr. Larry J. Anderson are co-inventors on the PneumoniaCheck™ patent licensed to MD Innovate, Inc. from US Centers for Disease Control and Prevention and Georgia Tech Research Corporation.

Grant information

Supported by internal grants from US Centers for Disease Control and Prevention and Emory University Hospital.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- Burns MW: **Precipitins to Klebsiella and Other Enterobacteria in the Serum of Patients with Chronic Respiratory Disorders.** *The Lancet.* 1968; 1(7539): 383–385.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Goddard AF, Staudinger BJ, Dowd SE, *et al.*: **Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota.** *Proc Natl Acad Sci U S A.* 2012; 109(34): 13769–13774.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Lentino JR, Lucks DA: **Nonvalue of Sputum Culture in the Management of Lower Respiratory Tract Infections.** *J Clin Microbiol.* 1987; 25(5): 758–762.
[PubMed Abstract](#) | [Free Full Text](#)
- Rosenfeld M, Emerson J, Accurso F, *et al.*: **Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis.** *Pediatr Pulmonol.* 1999; 28(5): 321–328.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gilchrist FJ, Salamat S, Clayton S, *et al.*: **Bronchoalveolar lavage in children with cystic fibrosis: how many lobes should be sampled?** *Arch Dis Child.* 2011; 96: 215–217.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Willner D, Haynes MR, Furlan M, *et al.*: **Spatial distribution of microbial communities in the cystic fibrosis lung.** *ISME J.* 2012; 6(2): 471–474.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Wimberley N, Faling LJ, Bartlett JG: **A Fiberoptic Bronchoscopy Technique to Obtain Uncontaminated Lower Airway Secretions for Bacterial Culture.** *Am Rev Respir Dis.* 1979; 119(3): 337–343.
[PubMed Abstract](#)
- Couch RB, Cate TR, Douglas RG Jr, *et al.*: **Effect of Route of Inoculation on Experimental Respiratory Viral Disease in Volunteers and Evidence for Airborne Transmission.** *Bacteriol Rev.* 1966; 30(3): 517–529.
[PubMed Abstract](#) | [Free Full Text](#)
- Couch RB, Cate TR, Gerone PJ, *et al.*: **Production of Illness with a Small-Particle Aerosol of Cocksackie A₂₂.** *J Clin Invest.* 1965; 44(4): 535–542.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Gerone PJ, Couch RB, Keefer GV, *et al.*: **Assessment of Experimental and Natural Viral Aerosols.** *Bacteriol Rev.* 1966; 30(3): 576–584.
[PubMed Abstract](#) | [Free Full Text](#)
- Lee N, Chan PK, Hui DS, *et al.*: **Viral loads and duration of viral shedding in adult patients hospitalized with influenza.** *J Infect Dis.* 2009; 200(4): 492–500.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Wainwright CE, France MW, O'Rourke P, *et al.*: **Cough-generated aerosols of *Pseudomonas aeruginosa* and other Gram-negative bacteria from patients with cystic fibrosis.** *Thorax.* 2009; 64(11): 926–931.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Knibbs LD, Johnson GR, Kidd TJ, *et al.*: **Viability of *Pseudomonas aeruginosa* in cough aerosols generated by persons with cystic fibrosis.** *Thorax.* 2014; 69(8): 740–745.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Liljemark WF, Gibbons RJ: **Proportional distribution and relative adherence of streptococcus miteor (*mitis*) on various surfaces in the human oral cavity.** *Infect Immun.* 1972; 6(5): 852–859.
[PubMed Abstract](#) | [Free Full Text](#)
- Hart MC, Orzalesi MM, Cook CD: **Relation between anatomic respiratory dead space and body size and lung volume.** *J Appl Physiol.* 1963; 18(3): 519–522.
[Reference Source](#)
- Scholz TL, Midha PA, Anderson LJ, *et al.*: **PneumoniaCheck: A Device for Sampling Lower Airway Aerosols.** *J Med Devices.* 2010; 4(4): 041005.
[Publisher Full Text](#)
- Cystic Fibrosis Foundation Patient Registry: 2013 Annual Data Report to the Center Directors. Bethesda, Maryland. 2014.
- Furness JC, Habel A, Spencer DA, *et al.*: **To the editor: Bronchoalveolar lavage (BAL) in pediatric cystic fibrosis (CF): its clinical use modified by audit in a regional CF center.** *Pediatr Pulmonol.* 2002; 33(3): 234.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lyczak JB, Cannon CL, Pier GB: **Lung infections associated with cystic fibrosis.** *Clin Microbiol Rev.* 2002; 15(2): 194–222.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Ramsey BW, Wentz KR, Smith AL, *et al.*: **Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients.** *Am Rev Respir Dis.* 1991; 144(2): 331–337.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Armstrong DS, Grimwood K, Carlin JB, *et al.*: **Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis.** *Pediatr Pulmonol.* 1996; 21(5): 267–275.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Harris JK, De Groote MA, Sagel SD, *et al.*: **Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis.** *Proc Natl Acad Sci U S A.* 2007; 104(51): 20529–20533.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Zemanick ET, Wagner BD, Harris JK, *et al.*: **Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.** *Pediatr Pulmonol.* 2010; 45(6): 569–577.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Oosterheert JJ, Bonten MJ, Buskens E, *et al.*: **Algorithm to determine cost savings of targeting antimicrobial therapy based on results of rapid diagnostic testing.** *J Clin Microbiol.* 2003; 41(10): 4708–4713.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Emery SL, Erdman DD, Bowen MD, *et al.*: **Real-time reverse transcription-polymerase chain reaction assay for SARS-associated coronavirus.** *Emer Infect Dis.* 2004; 10(2): 311–316.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Saiman L, Siegel J, Cystic Fibrosis Foundation: **Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.** *Infect Control Hosp Epidemiol.* 2003; 24(5 Suppl): S6–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Yankaskas JR, Marshall BC, Sufian B, *et al.*: **Cystic fibrosis adult care: consensus conference report.** *Chest.* 2004; 125(1 Suppl): 1S–39S.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Soyer OU, Dizdar EA, Keskin O, *et al.*: **Comparison of two methods for exhaled breath condensate collection.** *Allergy.* 2006; 61(8): 1016–1018.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Fennelly KP, Martyny JW, Fulton KE, *et al.*: **Cough-generated aerosols of *Mycobacterium tuberculosis*: a new method to study infectiousness.** *Am J Respir Crit Care Med.* 2004; 169(5): 604–609.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Fennelly KP, Jones-López EC, Ayakaka I, *et al.*: **Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis.** *Am J Respir Crit Care Med.* 2012; 186(5): 450–457.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Jones-López EC, Namugga O, Mumbowa F, *et al.*: **Cough aerosols of *Mycobacterium tuberculosis* predict new infection: a household contact study.** *Am J Respir Crit Care Med.* 2013; 187(9): 1007–1015.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Mehta T, McGrath E, Bheemreddy S, *et al.*: **Detection of oseltamivir resistance during treatment of 2009 H1N1 influenza virus infection in immunocompromised patients: utility of cycle threshold values of qualitative real-time reverse transcriptase PCR.** *J Clin Microbiol.* 2010; 48(11): 4326–4328.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Espy MJ, Uhl JR, Sloan LM, *et al.*: **Real-time PCR in clinical microbiology: applications for routine laboratory testing.** *Clin Microbiol Rev.* 2006; 19(1): 165–256.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Xu Z, Shen F, Li X, *et al.*: **Molecular and microscopic analysis of bacteria and viruses in exhaled breath collected using a simple impaction and condensing method.** *PLoS One.* 2012; 7(7): e41137.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Houspie L, De Coster S, Keyaerts E, *et al.*: **Exhaled breath condensate sampling is not a new method for detection of respiratory viruses.** *Viral J.* 2011; 8: 98.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Fabian P, McDevitt JJ, DeHaan WH, *et al.*: **Influenza virus in human exhaled breath: an observational study.** *PLoS One.* 2008; 3(7): e2691.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Huynh KN, Oliver BG, Stelzer S, *et al.*: **A new method for sampling and detection of exhaled respiratory virus aerosols.** *Clin Infect Dis.* 2008; 46(1): 93–95.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 03 October 2016

<https://doi.org/10.5256/f1000research.9959.r16745>

© 2016 Griffith D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

David E Griffith

Division of Infectious Diseases & Global Medicine, Department of Medicine, Comprehensive Heart and Lung Disease, The University of Texas Health Center at Tyler, Tyler, TX, USA

Comment #1: I am not familiar with the term Cycle Threshold, " C_T ". The term is introduced in the first paragraph of the Methods and then mentioned again in the last paragraph of the Methods. It would have been helpful to me to have had a brief discussion of this term in the Introduction or Methods. The C_T values were discussed in full paragraphs in the Results and Discussion sections so it is clearly an important metric for this study and there could be other readers not familiar with C_T .

Comment #2: Evaluation of microbiologic results in bronchiectasis patients is difficult. First, there is no "gold standard" test for identifying potential respiratory pathogens in the lungs of these patients. Microbiome studies suggest that a large number of potential respiratory pathogens populate the lungs of these patients but do not help determine which one(s) are responsible for symptoms or clinical deterioration and therefore might benefit from therapy. Similarly, microbiology results from BAL do not necessarily identify pathogens responsible for symptoms and clinical deterioration. I think these observations are pertinent with regard to the sensitivity and specificity claims of the authors. In Table 1, it is apparent that mouth flora is not sampled with the cough technique avoiding an important mechanism of specimen contamination. In Table 2, however, there is poor concordance between sputum and cough with regard to *Pseudomonas* and *Staph*, with these 2 potential pathogens isolated more commonly with sputum than cough. One interpretation of that observation is that sputum is more sensitive than cough for recovering potential respiratory pathogens in CF. The more frequent isolation of multiple respiratory pathogens with sputum could be interpreted the same way especially in light of the microbiome data. I am unsure where the authors believe the source of the "excess" *Pseudomonas* and *Staph* (as well as the specimens with multiple pathogens) is for sputum patients? Are they suggesting these "excess" isolates are "contaminants"?

Comment #3: I think the authors have convincingly shown that the PneumoniaCheck™ device avoids upper airway bacterial contamination during specimen collection with cough in CF patients. I think their findings with regard to the number and type of CF related respiratory pathogens and

the clinical significance of those pathogens remains to be elucidated.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 21 September 2016

<https://doi.org/10.5256/f1000research.9959.r16100>

© 2016 Kalin M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mats Kalin

Department of Infectious Diseases, Karolinska Institutet, Stockholm, Sweden

Ku *et al*, describe the experiences with a newly designed device for collecting cough specimens from patients with CF. The device is constructed with the intention that dead space air, presumably containing a high concentration of oral contaminants, should be collected separately, while on the other hand cough material from the lower lungs is to be collected on a specific filter constructed so that bacteria should be trapped in such a way that the material may be used for RT-PCR.

Title, abstract, methods and material are clearly described as is results. Discussion is adequate and relevant.

The presented results indicate high specificity with low risk of oral contaminants in cough specimens than in sputum from 20 adult CF individuals. Actually only 12 patients produced a sputum specimen, so it is a small study. However the differences were significant.

Sensitivity cannot be assessed with the way the study was carried out, but comparison with other studies indicate satisfactory results. Thus, the device seems to permit improved analysis of quantitative bacteriology in lower lung specimens from CF patients. The device is described as simple to use and is suggested to be used to follow lower respiratory tract microbiology in CF patients, so that increased concentrations of significant bacterial pathogens may be noted. This may be a step forward for the management of these patients. Further studies, including pediatric studies, are needed to corroborate the findings in this study and to explore the advantages of longitudinal follow up of CF patients

PCR may not suffice all the time, since bacterial resistance may have to be detected and specified in order to find an adequate treatment alternative. Needless to say this is an increasing problem.

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research